Table 3 Summary of recurrence events after CRT
Treatment | RT field | Dose (Gy) | Primary tumor site | Recurrence site | RFS (month) | Salvage treatment |
|---|---|---|---|---|---|---|
dCRT | ENI | 59.4 | Lt | Local | 7.1 | ESD |
dCRT | IFI | 60 | UtMtLt | Local | 7.2 | ESD |
dCRT | ENI | 59.4 | Mt | Local | 8.2 | ESD |
dCRT | ENI | 48.6 | Mt | Local | 18.9 | BSC |
dCRT | ENI | 59.4 | Mt | LN (in field) | 26.6 | Chemotherapy |
dCRT | ENI | 59.4 | Ut | Local | 31.8 | BSC |
dCRT | ENI | 59.4 | MtLt | Local | 47.5 | ESD |
dCRT | IFI | 65 | Mt | LN (in field), Pleura | 58.8 | Chemotherapy |
dCRT | ENI | 59.4 | LtMt | Local | 63.7 | ESD |
dCRT | ENI | 59.4 | Lt | Local | 76.7 | ESD |
ER-CRT | ENI | 40 | Mt | Lung | 1.4 | Local resection of lung |
ER-CRT | ENI | 39.6 | Mt | LN (out of field) | 13.1 | Chemotherapy |
ER-CRT | ENI | 28 | Lt | LN (in field) | 15.3 | Surgery |
ER-CRT | ENI | 40 | Mt | LN (in field) | 22.5 | Surgery |
ER-CRT | ENI | 50.4 | Mt | Local | 29.3 | ESD |
ER-CRT | ENI | 50.4 | Mt | LN (in field) | 31.0 | Chemotherapy |
ER-CRT | ENI | 39.6 | Lt | Local | 43.2 | ESD |
ER-CRT | ENI | 50.4 | Mt | Local | 52.2 | ESD |